The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response

Oncoimmunology. 2023 Dec 26;13(1):2297504. doi: 10.1080/2162402X.2023.2297504. eCollection 2024.

Abstract

IL-37 is a member of the IL-1 superfamily exerting anti-inflammatory functions in a number of diseases. Extracellular IL-37 triggers the inhibitory receptor IL-1R8 that is known to regulate different NK cell pathways and functional activities including their anti-tumor effect. However, the effect of IL-37 on human NK cell functions is still to be unveiled. This study aimed to investigate the functional effect of IL-37 in human NK cells activated with IL-15. We found that IL-37 enhanced both NK cell cytotoxic activity against different tumor cell lines and cytokines production. These effects were associated with increased phosphorylation of ERK and NF-Kb. The improved NK cell activity was also strictly related to a time-dependent GSK3β-mediated degradation of IL-1R8. The enhanced activation profile of IL-37 treated NK cells possibly due to IL-1R8 degradation was confirmed by the results with IL-1R8-silenced NK cells. Lastly, in line with these data, through the analysis of the TNM plot database of a large group of patients, IL-37 mRNA expression was found to be significantly lower in colon and skin cancers than in normal tissues. Colon adenocarcinoma and neuroblastoma patients with higher IL-37 mRNA levels had significantly higher overall survival, suggesting that the presence of IL-37 might be considered an independent positive prognostic factor for this tumor. Our results provide novel information on the mechanisms regulating IL-1R8 function in human NK cells, highlighting the IL-37-IL-1R8 axis as a potential new target to improve the anti-tumor immune response.

Keywords: Cancer; IL-1R8; IL-37; immunotherapy; natural killer cells.

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Colonic Neoplasms*
  • Cytokines / metabolism
  • Humans
  • Killer Cells, Natural / metabolism
  • RNA, Messenger / metabolism
  • RNA, Messenger / pharmacology

Substances

  • Cytokines
  • Anti-Inflammatory Agents
  • RNA, Messenger

Grants and funding

The work was supported by the Associazione Italiana per la Ricerca sul Cancro (project no. 5 × 10002018 Id 21147, project no. IG 2017 Id 19920 to LM and project n IG2022 Id 27065 to PV) and by the Italian Ministry of Health with “Current research funds” Ministero della Salute (grant no. RC-2020 OPBG to LM and EM) and Ministero della Salute‐Ricerca 5 × 10002023 to FRM and with grant RF GR-2018-12365485 to AP.